Viral immunology最新文献

筛选
英文 中文
Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection. Arexvy:全面回顾呼吸道合胞病毒疫苗带来的革命性保护。
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2024-02-05 DOI: 10.1089/vim.2023.0093
M Swathi
{"title":"Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection.","authors":"M Swathi","doi":"10.1089/vim.2023.0093","DOIUrl":"10.1089/vim.2023.0093","url":null,"abstract":"<p><p>The respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection in children and poses a significant risk to older adults. Developing a vaccine against RSV has been a priority, and the recently approved Arexvy vaccine has shown promise in preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older. This comprehensive review discusses the history of RSV, challenges in vaccine development, and the mechanism of action of Arexvy. The efficacy and safety of the vaccine are explored based on phase 3 clinical trial, demonstrating its effectiveness in preventing RSV-associated LRTD. The most common adverse reactions reported include injection site pain, fatigue, myalgia, headache, and arthralgia. Ongoing research focuses on the long-term effectiveness of Arexvy, including the need for booster doses and its impact on reducing RSV-associated hospitalizations. The potential of Arexvy to lessen the burden of RSV-related illnesses, particularly in vulnerable populations, is highlighted, emphasizing the importance of widespread immunization efforts and accessibility to this groundbreaking vaccine.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"12-15"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Long Noncoding RNA Negative Regulator of Interferon Response in the Regulation of Hantaan Virus Infection. 长非编码 RNA 干扰素反应负调控因子在调控汉坦病毒感染中的作用
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2024-02-06 DOI: 10.1089/vim.2023.0111
Yan Liang, Jiayi Zhan, Hongyan Shi, Wei Ye, Kaixuan Zhang, Jiayu Li, Wei Wang, Pingzhong Wang, Ying Zhang, Jianqi Lian, Xuyang Zheng
{"title":"The Role of Long Noncoding RNA Negative Regulator of Interferon Response in the Regulation of Hantaan Virus Infection.","authors":"Yan Liang, Jiayi Zhan, Hongyan Shi, Wei Ye, Kaixuan Zhang, Jiayu Li, Wei Wang, Pingzhong Wang, Ying Zhang, Jianqi Lian, Xuyang Zheng","doi":"10.1089/vim.2023.0111","DOIUrl":"10.1089/vim.2023.0111","url":null,"abstract":"<p><p>Hantaan virus (HTNV) is prevalent in Eurasia. It causes hemorrhagic fever with renal syndrome (HFRS). Long noncoding RNAs (lncRNAs) play key roles in regulating innate immunity. Among these, lncRNA negative regulator of interferon response (NRIR) was reported as an inhibitor of several interferon (IFN)-stimulated genes. Our results showed that: NRIR expression was upregulated by HTNV infection in a type I IFN-dependent manner. The expression of NRIR in CD14<sup>+</sup> monocytes from HFRS patients in acute phase was significantly higher than that in convalescent phase and healthy controls. HTNV infection in some HTNV-compatible cells was promoted by NRIR. NRIR negatively regulated innate immunity, especially IFITM3 expression. Localized in the nucleus, NRIR bound with HNRNPC, and knockdown of HNRNPC significantly weakened the effect of NRIR in promoting HTNV infection and restored IFITM3 expression. These results indicated that NRIR regulates the innate immune response against HTNV infection possibly through its interaction with HNRNPC and its influence on IFITM3.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"44-56"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study. 第三剂同源 BBIBP-CorV/CoronaVac 增强疫苗的免疫原性持续性:一项前瞻性开放标签研究。
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2023-12-18 DOI: 10.1089/vim.2023.0075
Na Ren, Zhihong Wang, Sikang Gao
{"title":"Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study.","authors":"Na Ren, Zhihong Wang, Sikang Gao","doi":"10.1089/vim.2023.0075","DOIUrl":"10.1089/vim.2023.0075","url":null,"abstract":"<p><p>The inactivated whole-virion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has been widely used in a two-dose schedule, but with insufficient data on the immunogenicity of homologous BBIBP-CorV/CoronaVac boosting vaccination and too little follow-up to assess the duration of the immunogenic response. We prospectively evaluated the immunogenicity of a third-dose BBIBP-CorV/CoronaVac boosting vaccination, with neutralizing titers against wild type and Omicron assessed at the baseline (immediately before the booster dose), and days 14, 28, 98, and 174 post the third-booster. Of 182 volunteers screened, 165 were assessed eligible for enrolment. No moderate/severe adverse events were observed during the term of the study. From the baseline to day 174 post the third booster, neutralizing titers against wild type and Omicron peaked by approximately sixfold increase (up to 811.83 and 33.40, respectively) at day 14 and slowly decreased over time. The geometric mean titers against Omicron were lower than against type with a 19.8-39. Sixfold reduction at all time points. The seropositivity against Omicron at the baseline, days 14, 28, 98, and 174 after the booster dose was 12.6%, 50.0%, 37.8%, 38.6%, and 22.8%, respectively. Data presented herein indicated that the BBIBP-CorV/CoronaVac booster significantly enhances the neutralizing potency against wild-type strain but elicited weaker neutralizing activity to Omicron. Our findings suggest that individuals receiving booster inactivated vaccine remain at risk for Omicron infection, which is crucial to inform ongoing and future vaccination strategies to combat coronavirus disease 2019.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"16-23"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138810894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interaction Between Genetic Susceptibility and COVID-19 Pathogenesis in Pediatric Multisystem Inflammatory Disorders: The Role of Immune Responses. 遗传易感性与 COVID-19 发病机制在小儿多系统炎症性疾病中的相互作用:免疫反应的作用
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI: 10.1089/vim.2023.0074
Li-Na Chen, Zhang-Xuan Shou, Xue Jin
{"title":"Interaction Between Genetic Susceptibility and COVID-19 Pathogenesis in Pediatric Multisystem Inflammatory Disorders: The Role of Immune Responses.","authors":"Li-Na Chen, Zhang-Xuan Shou, Xue Jin","doi":"10.1089/vim.2023.0074","DOIUrl":"10.1089/vim.2023.0074","url":null,"abstract":"<p><p>Numerous studies have highlighted the emergence of coronavirus disease (COVID-19) symptoms reminiscent of Kawasaki disease in children, including fever, heightened multisystem inflammation, and multiorgan involvement, posing a life-threatening complication. Consequently, extensive research endeavors in pediatric have aimed to elucidate the intricate relationship between COVID-19 infection and the immune system. COVID-19 profoundly impacts immune cells, culminating in a cytokine storm that particularly inflicts damage on the pulmonary system. The gravity and vulnerability to COVID-19 are closely intertwined with the vigor of the immune response. In this context, the human leukocyte antigen (HLA) molecule assumes pivotal significance in shaping immune responses. Genetic scrutiny of HLA has unveiled the presence of at least one deleterious allele in children afflicted with multisystem inflammatory syndrome in children (MIS-C). Furthermore, research has demonstrated that COVID-19 exploits the angiotensin-converting enzyme 2 (ACE-2) receptor, transmembrane serine protease type 2, and various other genes to gain entry into host cells, with individuals harboring ACE-2 polymorphisms being at higher risk. Pediatric studies have employed diverse genetic methodologies, such as genome-wide association studies (GWAS) and whole exome sequencing, to scrutinize target genes. These investigations have pinpointed two specific genomic loci linked to the severity and susceptibility of COVID-19, with the HLA locus emerging as a notable risk factor. In this comprehensive review article, we endeavor to assess the available evidence and consolidate data, offering insights into current clinical practices and delineating avenues for future research. Our objective is to advance early diagnosis, stabilization, and appropriate management strategies to mitigate genetic susceptibility's impact on the incidence of COVID-19 in pediatric patients with multisystem inflammation.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interleukin-36gamma Mediates the In Vitro Activation of CD8+ T Cells from Patients Living with Chronic Human Immunodeficiency Virus-1 Infection. 白细胞介素-36γ介导慢性人类免疫缺陷病毒-1 感染患者 CD8+ T 细胞的体外激活。
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2024-02-01 DOI: 10.1089/vim.2023.0080
Yingquan Zhou, Jijun Chen, Shaoli Bai, Fan Yang, Ruqing Yan, Yanjun Song, Binfa Yang, Chao Li, Jianyun Wang
{"title":"Interleukin-36gamma Mediates the <i>In Vitro</i> Activation of CD8<sup>+</sup> T Cells from Patients Living with Chronic Human Immunodeficiency Virus-1 Infection.","authors":"Yingquan Zhou, Jijun Chen, Shaoli Bai, Fan Yang, Ruqing Yan, Yanjun Song, Binfa Yang, Chao Li, Jianyun Wang","doi":"10.1089/vim.2023.0080","DOIUrl":"10.1089/vim.2023.0080","url":null,"abstract":"<p><p>Interleukin-36 (IL-36) signaling plays an important role in promoting CD8<sup>+</sup> T cell-mediated antitumor immune responses. The role of IL-36 signaling in CD8<sup>+</sup> T cells that are involved in host immune responses during human immunodeficiency virus-1 (HIV-1) infection has not been characterized. Sixty-one patients living with chronic HIV-1 infection and 23 controls were enrolled in this study. The levels of IL-36 cytokine family members were measured by enzyme-linked immunosorbent assay. Purified CD8<sup>+</sup> T cells were stimulated with recombinant IL-36gamma (1 or 10 ng/mL). The expression of inhibitory receptors, the secretion of cytotoxic molecules and interferon-gamma, and the mRNA levels of apoptosis-related ligands were assessed to evaluate the effect of IL-36gamma on CD8<sup>+</sup> T cell function <i>in vitro</i>. There were no significant differences in IL-36alpha, IL-36beta, or IL-36 receptor antagonist levels between patients living with chronic HIV-1 infection and controls. Plasma IL-36gamma levels were reduced in patients living with chronic HIV-1 infection. Perforin, granzyme B, and granulysin secretion, as well as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) mRNA expression, but not programmed death-1 (PD-1) or cytotoxic T lymphocyte-associated protein-4 (CTLA-4) expression was downregulated in CD8<sup>+</sup> T cells from patients living with chronic HIV-1 infection. The addition of both 1 and 10 ng/mL IL-36gamma enhanced perforin, granzyme B, granulysin, and interferon-gamma secretion by CD8<sup>+</sup> T cells without affecting PD-1/CTLA-4 or TRAIL/FasL mRNA expression in CD8<sup>+</sup> T cells from patients living with chronic HIV-1 infection. The addition of 1 ng/mL IL-36gamma also promoted perforin and granzyme B secretion by HIV-1-specific CD8<sup>+</sup> T cells from patients living with chronic HIV-1 infection. The reduced IL-36gamma levels in patients living with chronic HIV-1 infection might be insufficient for the activation of CD8<sup>+</sup> T cells, leading to CD8<sup>+</sup> T cell exhaustion.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"24-35"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Different Cofactors on Naturally Acquired Human Papillomavirus Antibody Levels Among Unvaccinated Pregnant Women. 不同辅因子对未接种疫苗孕妇自然获得的人类乳头瘤病毒抗体水平的影响
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2024-02-05 DOI: 10.1089/vim.2023.0108
Laura Kirjavainen, Helmi Suominen, Kari Syrjänen, Tim Waterboer, Seija Grenman, Stina Syrjänen, Karolina Louvanto
{"title":"Impact of Different Cofactors on Naturally Acquired Human Papillomavirus Antibody Levels Among Unvaccinated Pregnant Women.","authors":"Laura Kirjavainen, Helmi Suominen, Kari Syrjänen, Tim Waterboer, Seija Grenman, Stina Syrjänen, Karolina Louvanto","doi":"10.1089/vim.2023.0108","DOIUrl":"10.1089/vim.2023.0108","url":null,"abstract":"<p><p>Human papillomavirus (HPV) infections are common, transmitted by sexual and nonsexual routes. The present case-control setting was designed to examine potential cofactors associated with either persistently low or high HPV-antibody levels. The study subjects were from the Finnish HPV Family cohort of 329 baseline pregnant, non-HPV-vaccinated women, who were sampled for genital and oral HPV-DNA and HPV serology at baseline, and at 12, 24, and 36 months. Antibodies to the L1 major capsid protein of HPV 6, 11, 16, 18, and 45 were analyzed by multiplex HPV serology and HPV genotyping was performed. This study included 59 women, 23 women with persistently low (<200 median fluorescence intensity [MFI]) and 36 women with persistently high and always positive (>200 MFI) levels of these antibodies for all five HPV genotypes. Potential HPV-associated covariates were derived from detailed questionnaires. Only cofactors other than detected HPV genotype significantly impact on the levels of natural HPV antibodies. A higher number of past sexual partners or a history of diagnosed genital warts were significant covariates of high HPV antibody levels (<i>p</i> = 0.023 and <i>p</i> = 0.043, respectively). Of interest, women with a history of allergies presented with low levels of HPV antibodies (<i>p</i> = 0.03), potentially exposing these women to an increased risk of future HPV-related diseases that merit closer surveillance.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"36-43"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgment of Reviewers 2023. 鸣谢 2023 年审稿人。
IF 2.2 4区 医学
Viral immunology Pub Date : 2024-01-01 Epub Date: 2023-12-08 DOI: 10.1089/vim.2023.29062.ack
{"title":"Acknowledgment of Reviewers 2023.","authors":"","doi":"10.1089/vim.2023.29062.ack","DOIUrl":"10.1089/vim.2023.29062.ack","url":null,"abstract":"","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":"37 1","pages":"57-58"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139983854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intracellular Toll-Like Receptors Modulate Adaptive Immune Responses in Head and Neck Cancer 细胞内 Toll-Like 受体调节头颈癌的适应性免疫反应
IF 2.2 4区 医学
Viral immunology Pub Date : 2023-12-08 DOI: 10.1089/vim.2023.0079
S. Nayanar, Deepak Roshan V.G., Shruthi Surendran, G. Kjeller, B. Hasséus, Daniel Giglio
{"title":"Intracellular Toll-Like Receptors Modulate Adaptive Immune Responses in Head and Neck Cancer","authors":"S. Nayanar, Deepak Roshan V.G., Shruthi Surendran, G. Kjeller, B. Hasséus, Daniel Giglio","doi":"10.1089/vim.2023.0079","DOIUrl":"https://doi.org/10.1089/vim.2023.0079","url":null,"abstract":"","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":"33 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138589122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viral Biology and Immune Privilege in the Development of Extrahepatic Manifestations During Hepatitis E Virus Infection 戊型肝炎病毒感染期间出现肝外表现的病毒生物学和免疫特权
IF 2.2 4区 医学
Viral immunology Pub Date : 2023-12-08 DOI: 10.1089/vim.2023.0096
Javier Orozco-Cordoba, Camila Mazas, Gisela Du Pont, Edmundo Lamoyi, Graciela Cárdenas, Nora A. Fierro
{"title":"Viral Biology and Immune Privilege in the Development of Extrahepatic Manifestations During Hepatitis E Virus Infection","authors":"Javier Orozco-Cordoba, Camila Mazas, Gisela Du Pont, Edmundo Lamoyi, Graciela Cárdenas, Nora A. Fierro","doi":"10.1089/vim.2023.0096","DOIUrl":"https://doi.org/10.1089/vim.2023.0096","url":null,"abstract":"","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":"62 5","pages":""},"PeriodicalIF":2.2,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138587129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Recombinant Enzyme-Linked Immunosorbent Assay for the Detection of Antibodies Against Infectious Bronchitis Virus. 用于检测传染性支气管炎病毒抗体的重组酶联免疫吸附法的开发。
IF 2.2 4区 医学
Viral immunology Pub Date : 2023-12-01 Epub Date: 2023-10-30 DOI: 10.1089/vim.2023.0049
Yu Zhang, Zongxi Han, Huixin Li, Shengwang Liu
{"title":"Development of a Recombinant Enzyme-Linked Immunosorbent Assay for the Detection of Antibodies Against Infectious Bronchitis Virus.","authors":"Yu Zhang, Zongxi Han, Huixin Li, Shengwang Liu","doi":"10.1089/vim.2023.0049","DOIUrl":"10.1089/vim.2023.0049","url":null,"abstract":"<p><p>Infectious bronchitis virus (IBV), a gammacoronavirus within the Coronaviridae family, is an economically important etiological disease agent in chickens. Both early diagnosis and determination of the immune status of chickens are important for controlling IBV outbreaks in chicken flocks. The N protein is the most abundantly expressed virus-derived protein during IBV infection and can induce a strong immune response by producing antibodies during early infection or immunization. In this study, we found that the amino acid sequences of the N protein between CK/CH/LJL/04I and the other 22 IBVs were conserved, especially in the 1-160 amino acid region. Based on the sequence similarities, the three recombinant proteins, rN160 (amino acid positions 1-160), rN266 (144-409), and rN409 (1-409), were expressed using the <i>Escherichia coli</i> system and subsequently purified. The results demonstrated that the antigenicity and reactivity of rN160 were better than those of rN266 and rN409. As a result, an indirect enzyme-linked immunosorbent assay (ELISA) (rN160 ELISA) was developed to detect the IBV antibody based on the rN160 protein. Using 1,500 clinical field serum samples, the relative sensitivity, specificity, and accuracy of the rN160 ELISA were 98.97%, 92.34%, and 97.93%, respectively, compared to those of a commercial ELISA kit (IDEXX), indicating a strong positive correlation between the two methods. Taken together, these results reveal that the rN160 ELISA is a rapid, simple, and sensitive method for detecting group-specific IBV antibodies for epidemiological investigation and antibody-level monitoring.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":" ","pages":"649-658"},"PeriodicalIF":2.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71414118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信